WS
AVEO

Wedbush Securities’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Wedbush Securities’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,700
Closed -$55K – 1050
2020
Q2 		$55K Buy
+10,700
New +$67.5K 0.01% 899
2020
Q1 		– Sell
-2,000
Closed -$12K – 1048
2019
Q4 		$12K Buy
+2,000
New +$14.7K ﹤0.01% 988

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Wedbush Securities's AVEO Position: Q3 2020 in Review

Wedbush Securities sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2020, closing a stake of 10,700 shares — an estimated $55K sold.

Wedbush Securities first reported a position in AVEO in Q4 2019 and held it in 2 quarters. The position peaked at $55K in Q2 2020. 63 funds tracked by Wall St. Rank hold AVEO as of Q3 2020.

  • Wedbush Securities reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 10,700 AVEO Pharmaceuticals, Inc. shares in Q3 2020, an estimated $55K.
  • Wedbush Securities first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Wedbush Securities's AVEO Pharmaceuticals, Inc. position peaked at $55K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.